PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients
نویسندگان
چکیده
منابع مشابه
PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients
Introduction Canakinumab is a recombinant monoclonal fully human antibody against Interleukin-1b and approved for the treatment of CAPS in many countries including Europe and the US. Current dose recommendations are 150 mg (body weight >40 kg) respectively 2 mg/kg body weight (15 to 40 kg) every 8 weeks but yield insufficient response in some individuals, especially in children and patients wit...
متن کاملPW02-041 - Canakinumab treatment regimens in CAPS-patients
Introduction Canakinumab is a recombinant monoclonal fully human antibody against Interleukin-1b and currently the only drug approved for the treatment of CAPS in Europe. Current dose recommendations are 150mg (body weight >40kg) respectively 2mg/kg bodyweight (15 to 40kg) every 8 weeks but yield insufficient response in some individuals, especially in children and patients with severe phenotyp...
متن کاملPReS-FINAL-2330: Canakinumab treatment in patients with HIDS
Introduction Hyper-IgD and periodic-fever syndrome (HIDS) is a recessively inherited-autoinflammatory condition caused by mevalonate-kinase mutations. It is characterized by early-onset (<1 year of age), 4-6 days-long acute inflammatory episodes that typically recur every 4-6 weeks. The main features during episodes include fever, lymphadenopathies, rash, headache, abdominal pain, diarrhea, and...
متن کاملPReS-FINAL-2240: Serum amyloid protein a concentration in CAPS patients treated with anti IL1Β
Introduction Although all patients with chronic inflammatory conditions are at risk for developing type AA amyloidosis, the incidence varies widely between the different Autoinflammatory syndromes. The reported incidence is about 35% of patients with CAPS (cryopyrin-associated periodic syndrome) which comprises familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome and CINCA (chr...
متن کاملPReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy
PReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy N Nirmala, N Wulffraat, H Brunner, P Quartier, R Brik, L Mccann, H Ozdogan, L Rutkowska-Sak, R Schneider, V Gerloni, L Harel, M Terreri, K Houghton, R Joos, D Kingsbury, J Lopez-Benitez, S Radominski, A Brachat, S Bek, M Schumacher, M Valentin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Rheumatology
سال: 2013
ISSN: 1546-0096
DOI: 10.1186/1546-0096-11-s2-p214